Search database
LIST OPTIONS
Filter
5
Filtered Results: 5
Text search: , S. Eymard-Duvernay
Featured
Language
Document type
Studies & Reports
2
Guidelines
2
No document type
1
Countries / Regions
Cameroon
1
Authors & Publishers
World Health Organisation (WHO)
2
World Health Organization WHO
2
, S. Eymard-Duvernay
1
A. Cournil
1
E Clinical Medecine (Published by the Lancet)
1
Elsevier
1
et al.
1
G. F. Tchouwa
1
Publication Years
Category
Toolboxes
Drug resistance
4
ART Drug Resistance
2
HIV testing & services
1
Laboratory
1
EClinicalMedicine 1 (2018) 21–27 https://doi.org/10.1016/j.eclinm.2018.06.005 2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). EClinicalMedicine: journal homepage: https://www.jo... more
HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it ... more
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les populations sous TAR. Bien que la résistance au DT... more
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este antirretrovírico en las poblaciones tratadas con esquemas que lo conti... more